Abstracts tagged "thrombosis and treatment"

Abstract Number: 2166 • 2018 ACR/ARHP Annual Meeting
Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review
Iustina Janta¹, Roberto González², Tania Gudu³ and Indalecio Monteagudo¹, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ³University of Medicine Carol Davila Bucuresti, Romania, Bucuresti, Romania
Background/Purpose: Venous thrombosis (VT) is a serious and potentially life-threatening manifestation of Behçet disease (BD). However, there is little evidence of the management of the…
Abstract Number: 2668 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Pratyaksha Sankhyan¹, Boonphiphop Boonpheng² and Christopher Cook², ¹Internal Medicine, East Tennessee State University, Johnson city, TN, ²Internal Medicine, East Tennessee State University, johnson city, TN
Hydroxychloroquine and Risk of Thrombosis in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysisAuthors : Sankhyan P, Boonpheng B, Cook CT Background/Purpose: Over…
Abstract Number: 7 • 2014 ACR/ARHP Annual Meeting
Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients
Chary Lopez-Pedrera¹, Carlos Perez-Sanchez¹, Ángeles Aguirre Zamorano¹, Nuria Barbarroja¹, Patricia Ruiz-Limon¹, Yolanda Jiménez Gómez¹, Munther A. Khamashta², Antonio Rodriguez-Ariza³, Jose Antonio Gonzalez-Reyes⁴, Jose Manuel Villalba⁵, Eduardo Collantes-Estevez¹ and Mª Jose Cuadrado⁶, ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Cell Biology, Physiology, and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ⁵Cell Biology, Physiology and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ⁶Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose To investigate the beneficial effects of in vivoubiquinol (Q) supplementation on athero-thrombosis prevention in APS patients. Methods The study was performed on 10 APS…
Abstract Number: 2460 • 2012 ACR/ARHP Annual Meeting
Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with　antiphospholipid Syndrome
Yuichiro Fujieda¹, Olga Amengual², Toshiyuki Watanabe¹, Michihito Kono², Yusaku Kanetsuka², Takashi Kurita², Toshio Odani¹, Kotaro Otomo¹, Toshiyuki Bohgaki², Tetsuya Horita², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Medicine II, Hokkaido University, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Arterial thrombosis (AT) is a major clinicalmanifestation of the antiphospholipid syndrome (APS). A number of studies have evaluated the rate of recurrent thromboembolism, including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].